Mesoblast (MSB)

Business description

Mesoblast is developing adult stem cell therapies based on its proprietary MPC and culture-expanded MSC platforms. It has six late-stage clinical trials across four areas.

Share price chart

Share chart

Stock data

Market cap.A$1274.2m
Last closeA$3.75
High / Low (52 weeks)A$5.8 / A$3.2
Stock market listingAU
Forecast net cash (A$m)94.5
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & Healthcare

Price performance

%1m3m12m
Actual6.8(10.7)(19.9)
Relative *7.8(12)(25.1)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Ablynx
Abzena Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Addex Therapeutics
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris Agennix
Alchemia Alexza Pharmaceuticals
Algeta ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Animalcare Group Anteo Diagnostics
Anthera Pharmaceuticals Aratana Therapeutics
Ardea Biosciences Ardelyx
Arena Pharmaceuticals arGEN-X
Argos Therapeutics Ariad Pharmaceuticals
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Astex Pharmaceuticals Athersys
Avacta Group AVEO Pharmaceuticals
Avita Medical Balda
Basilea Bavarian Nordic
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLight Life Sciences Inv BioLineRx
Bionomics Bionor Pharma
Biota Holdings Biotie Therapies Corp
Biotron Bluebird Bio
BTG Can-Fite BioPharma
Capstone Therapeutics Cardio3 BioSciences
Carmat Celldex Therapeutics
Cellectis Cerulean
Circadian Technologies Clavis Pharma
Cleveland BioLabs Clinigen Group
Clinuvel Consort Medical
Curis Cytori Therapeutics
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Delcath Systems Deltex Medical
Derma Sciences DiaSorin
Diaxonhit e-Therapeutics
EKF Diagnostics Emergent BioSolutions
Endocyte Epigenomics
Epistem Holdings Erytech Pharma
Esperion Therapeutics Evolva
Evotec Exact Sciences
Exelixis Formycon
Futura Medical Galapagos
Galmed Pharmaceuticals Genfit
Genmab GeoVax
GI Dynamics Gilead Sciences
GNI Group Ltd GW Pharmaceuticals
Halozyme Therapeutics Horizon Discovery
Hutchison China MediTech Hybrigenics
iCo Therapeutics Idenix
Immune Pharmaceuticals Immunodiagnostic Systems Holdings
ImmuPharma Imugene
Incyte Corporation Infinity Pharmaceuticals
Innate Pharma Insmed
Invion Ion Beam Applications
Ipsogen Ironwood Pharmaceuticals
Islet Sciences Ixico
KaloBios Pharmaceuticals Karolinska Development
Keryx Biopharmaceuticals LCA-Vision
LeMaitre Vascular Lifeline Scientific
Ligand Pharmaceuticals Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
MediciNova Medigene
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals MethylGene
Midatech Molecular Partners
MolMed Mologen AG
Momenta Pharmaceuticals MorphoSys
Nanobiotix Nanosonics
Nektar Therapeutics NeoStem
Neovacs Newron Pharmaceuticals
NicOx NMC Health
NorDiag Nordion
NovaBay Pharmaceuticals Novogen
NPS Pharmaceuticals Ocata Therapeutics
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onxeo
Onyx Pharmaceuticals OPMEDIC Group
Optos Orexigen Therapeutics
Orexo Ossur
OvaScience Oxford BioMedica
Pacific Edge Paion
Paladin Labs Patheon
Pharmacyclics Pharmaxis
Pharming Group Photocure
Phylogica Prescient Therapeutics
Prima BioMed ProMetic Life Sciences
Prosensa Proteome Sciences
QRxPharma Quantum Pharmaceuticals
Regeneus Relmada Therapeutics
ReNeuron Group Resverlogix
REVA Medical Sangamo BioSciences
Sarepta Therapeutics Sartorius
Scancell Selvita
Simavita Sinclair Pharma
Sirtex Medical Skyepharma
Smith & Nephew Sobi
Sosei Group Corporation Source Bioscience
SQI Diagnostics Stallergenes
StemCells Stentys
Stratec Biomedical Sucampo Pharmaceuticals
Sunesis Pharmaceuticals Surgical Innovations
Sygnis SymBio Pharmaceuticals
Synairgen Synergy Health
Synta Pharmaceuticals Tekmira
TESARO Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Tissue Therapies
Tonix Pharmaceuticals Topotarget
Transgene Trillium Therapeutics
Trimel Pharmaceuticals UCB
UDG Healthcare uniQure NV
Vectura Verastem
Verisante Technology Vernalis
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus WaferGen Biosystems
Wilex Xencor
Zafgen Zealand Pharma
Zeltia Ziopharm Oncology

Company news

Here's why Mesoblast Limited shares soared 24% today

Mon, 13 Apr 2015 04:03:37 GMT

Mesoblast Key Patent Allowed in Japan for the Treatment of Heart Diseases ...

Thu, 26 Mar 2015 23:48:45 GMT

Key Mesoblast Patent Granted in the United States for the Treatment of ...

Mon, 09 Feb 2015 23:37:30 GMT

Celgene And Mesoblast Enter Into Equity Placement and Right of First Refusal ...

Mon, 13 Apr 2015 00:00:00 GMT

MESOBLAST ACQUIRES OSIRIS' CULTURE EXPANDED STEM CELL ...

Fri, 11 Oct 2013 00:29:06 GMT

Y/E Jun Revenue (A$m) EBITDA (A$m) PBT (A$m) EPS (c) P/E (x) P/CF (x)
2013A 24.2 (58.7) (48.8) (17.21) N/A N/A
2014A 27.5 (77.4) (68.8) (21.53) N/A N/A
2015E 37.8 (92.0) (88.8) (27.38) N/A N/A
2016E 19.7 (101.4) (98.7) (30.44) N/A N/A

Last updated on 30/03/2015

Investment summary

Mesoblast's product pipeline continues to mature as key milestones are met. Phase III trials for MPV-06-ID in low back pain were recently initiated following positive 24-month results showing that a single injection of allogeneic mesenchymal precursor cells, MPC-06-ID, induced substantial and sustained pain relief over 24 months. The filing of MSC-100-IV by partner JCR Pharma in graft vs host disease (GvhD) in Japan last October marked Mesoblast's first product submission. Filing is planned in paediatric aGvhD in 2016 in the US on the back of an open-label Phase III trial currently in progress, while positive interim data from a 160 patient paediatric trial were recently presented at the American Society for Blood and Marrow Transplantation meeting. Phase III trials also started in 2014 for MPC-150-IM in congestive heart failure. Interim data are expected in mid 2016 and top-line data in mid 2017. Our forecasts are currently under review.

Last updated on 31/03/2015

Industry outlook

Mesoblast is the leading mesenchymal stem cell development company, with two technology platforms (MPCs, MSCs) and nine clinical candidates in Phase III and Phase II. Its three alliances – with Teva, JCR and Lonza – underpin the key late-stage programmes.

Last updated on 31/03/2015

Key management

Company address

Level 39
55 Collins Street
Melbourne 3000
Australia
+61 3 9639 6036
View website